GEn1E Lifesciences
Biotechnology Research • 
El Camino Real, Palo Alto, United States • 11-20 Employees
Company overview
| Headquarters | El Camino Real, Palo Alto, United States |
| Websites | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Drug Discovery, Inflammation, Small Molecules, Machine Learning, Rare Diseases, Drug Development, Immunology, Inflammatory Disease, Ai Platform, Immunomodulators, Novel Drugs, Multi-Target, Ards, Y Combinator, Clinical Stage, Next-Generation, Techbio, Precision Therapies |
| Founded | 2019 |
| Employees | 11-20 |
| Socials |
Key Contact at GEn1E Lifesciences
Ritu Lal
Ceo And Co-Founder
GEn1E Lifesciences Email Formats
GEn1E Lifesciences uses 2 email formats. The most common is {first name} (e.g., john@gen1elifesci.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@gen1elifesci.com | 66.7% |
{first initial} | j@gen1elifesci.com | 33.3% |
About GEn1E Lifesciences
GEn1E Lifesciences is a clinical-stage, Phase 2 company accelerating 1st-in-class precision therapies for Immunology, Inflammatory and rare diseases with unprecedented efficiencies using AI. We are enrolling patients for Phase 2 study in the US and the differentiated mechanism of action (MOA) of our next generation kinase modulators has been published in JPET (Journal of Pharmacology and Experimental Therapeutics). We are based in Palo Alto, with a laboratory in Mountain View and are advancing 4 products, with the lead compound accelerated from early discovery to Phase 2 in 2.5 years and seed funding. This program has received Fast Track designation from the FDA and has a partnership with BARDA for precision approach using AI-powered endotyping in clinical studies. Using our well-differentiated "Platform-in-a-Mechanism" development model, GEn1E is advancing three additional drugs, with the two oral therapies for Chronic Diseases close to starting Phase 1. The 4th product is for pancreatic cancer. The team has a track record of drug development and AI with the founder and CEO, Dr. Ritu Lal, having 3 FDA approvals in the US and in Japan.
GEn1E Lifesciences revenue & valuation
| Annual revenue | $1,197,770 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,900,000 |
| Total funding | $34,000,000 |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
GEn1E Lifesciences has 6 employees across 5 departments.
Departments
Number of employees
Funding Data
Explore GEn1E Lifesciences's funding history, including investment rounds, total capital raised, and key backers.
GEn1E Lifesciences Tech Stack
Discover the technologies and tools that power GEn1E Lifesciences's digital infrastructure, from frameworks to analytics platforms.
CDN
CDN
Security
JavaScript libraries
Tag managers
Hosting
UI frameworks
Ecommerce
Miscellaneous
Security
Miscellaneous
Singapore
BelgiumFrequently asked questions
4.8
40,000 users
